Loading…
Development of Matrix Patches for Transdermal Delivery of a Highly Lipophilic Antiestrogen
Abstract The aim of this study was to develop matrix-type transdermal systems (TDSs) containing the highly lipophilic (log P = 5.82) antiestrogen (AE) and the permeation enhancers propylene glycol and lauric acid. For that purpose, permeation of AE from various adhesive matrices through excised skin...
Saved in:
Published in: | Drug development and industrial pharmacy 2003-01, Vol.29 (7), p.785-793 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c447t-a9ce51dfa6b37129ed2819e3d83346c0aaef8b0b5553d07f11fec1bbf47fd0983 |
---|---|
cites | cdi_FETCH-LOGICAL-c447t-a9ce51dfa6b37129ed2819e3d83346c0aaef8b0b5553d07f11fec1bbf47fd0983 |
container_end_page | 793 |
container_issue | 7 |
container_start_page | 785 |
container_title | Drug development and industrial pharmacy |
container_volume | 29 |
creator | Funke, Adrian Peter Günther, Clemens Müller, Rainer Helmut Lipp, Ralph |
description | Abstract
The aim of this study was to develop matrix-type transdermal systems (TDSs) containing the highly lipophilic (log P = 5.82) antiestrogen (AE) and the permeation enhancers propylene glycol and lauric acid. For that purpose, permeation of AE from various adhesive matrices through excised skin of hairless mice was evaluated. It was found that pretreatment of the skin with permeation enhancers raised the transdermal flux of subsequently applied antiestrogen. Highest steady-state transdermal fluxes (1.1 µg cm−2 h−1) were obtained from Gelva®, polyacrylate adhesive, followed by 0.55 µg cm−2 h−1 from Oppanol® polyisobutylene, 0.31 µg cm−2 h−1 from BIO-PSA® silicone, and 0.12 µg cm−2 h−1 from Sekisui polyacrylate matrices. In order to develop TDS with high content of fluid permeation enhancer propylene glycol, two different strategies were investigated. One strategy was the addition of hydroxypropyl cellulose (HPC) as thickening agent to Gelva matrices. This allowed for propylene glycol loading levels of up to 30%, resulting in transdermal AE fluxes of 0.09 µg cm−2 h−1. On the other hand, a fleece-laminated backing foil was loaded with the described permeation enhancer formulation and laminated with polyacrylate adhesive layer, resulting in transdermal AE fluxes of 0.06 µg cm−2 h−1. However, application of these TDSs on skin pretreated with permeation enhancers raised the fluxes to 2.6 µg cm−2 h−1 from Gelva HPC and 0.46 µg cm−2 h−1 from fleece Sekisui. |
doi_str_mv | 10.1081/DDC-120021778 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73525372</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73525372</sourcerecordid><originalsourceid>FETCH-LOGICAL-c447t-a9ce51dfa6b37129ed2819e3d83346c0aaef8b0b5553d07f11fec1bbf47fd0983</originalsourceid><addsrcrecordid>eNqF0bFv1DAUBnALgehRGFmRF7qF2nEcJ2N1BxTpKhjKwmK9OM-NKycOdq70_ntc3UHFUDG95feeP30m5C1nHzhr-Plmsy54yVjJlWqekRWXJSukqsvnZMVELYqWVfKEvErpljFetlK-JCd5slqIekV-bPAOfZhHnBYaLL2CJbp7-g0WM2CiNkR6HWFKPcYRPN2gd3cY9w8U6KW7Gfyebt0c5sF5Z-jFtDhMSww3OL0mLyz4hG-O85R8__Txen1ZbL9-_rK-2BamqtRSQGtQ8t5C3QmVg2FfNrxF0TdCVLVhAGibjnVSStEzZTm3aHjX2UrZnrWNOCVnh7tzDD93-XU9umTQe5gw7JJWQpZSqPK_kCvZ1lXDMiwO0MSQUkSr5-hGiHvNmX5oXefW9d_Ws393PLzrRuwf9bHmDN4fASQD3uZGjUuPrmplJVmVXXNwbsrNj_ArRN_rBfY-xD9L4qkM6p_VAcEvg4GI-jbs4pR_4In0vwGrMq6u</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17596480</pqid></control><display><type>article</type><title>Development of Matrix Patches for Transdermal Delivery of a Highly Lipophilic Antiestrogen</title><source>EBSCOhost Business Source Ultimate</source><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Funke, Adrian Peter ; Günther, Clemens ; Müller, Rainer Helmut ; Lipp, Ralph</creator><creatorcontrib>Funke, Adrian Peter ; Günther, Clemens ; Müller, Rainer Helmut ; Lipp, Ralph</creatorcontrib><description>Abstract
The aim of this study was to develop matrix-type transdermal systems (TDSs) containing the highly lipophilic (log P = 5.82) antiestrogen (AE) and the permeation enhancers propylene glycol and lauric acid. For that purpose, permeation of AE from various adhesive matrices through excised skin of hairless mice was evaluated. It was found that pretreatment of the skin with permeation enhancers raised the transdermal flux of subsequently applied antiestrogen. Highest steady-state transdermal fluxes (1.1 µg cm−2 h−1) were obtained from Gelva®, polyacrylate adhesive, followed by 0.55 µg cm−2 h−1 from Oppanol® polyisobutylene, 0.31 µg cm−2 h−1 from BIO-PSA® silicone, and 0.12 µg cm−2 h−1 from Sekisui polyacrylate matrices. In order to develop TDS with high content of fluid permeation enhancer propylene glycol, two different strategies were investigated. One strategy was the addition of hydroxypropyl cellulose (HPC) as thickening agent to Gelva matrices. This allowed for propylene glycol loading levels of up to 30%, resulting in transdermal AE fluxes of 0.09 µg cm−2 h−1. On the other hand, a fleece-laminated backing foil was loaded with the described permeation enhancer formulation and laminated with polyacrylate adhesive layer, resulting in transdermal AE fluxes of 0.06 µg cm−2 h−1. However, application of these TDSs on skin pretreated with permeation enhancers raised the fluxes to 2.6 µg cm−2 h−1 from Gelva HPC and 0.46 µg cm−2 h−1 from fleece Sekisui.</description><identifier>ISSN: 0363-9045</identifier><identifier>EISSN: 1520-5762</identifier><identifier>DOI: 10.1081/DDC-120021778</identifier><identifier>PMID: 12906336</identifier><language>eng</language><publisher>Colchester: Informa UK Ltd</publisher><subject>Adhesives - therapeutic use ; Administration, Cutaneous ; Animals ; Antiestrogen ; Biological and medical sciences ; Chemistry, Pharmaceutical - methods ; Estrogen Receptor Modulators - pharmacokinetics ; General pharmacology ; Highly lipophilic drug ; In Vitro Techniques ; Lauric acid ; Male ; Medical sciences ; Mice ; Mice, Hairless ; Permeability - drug effects ; Permeation enhancers ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; Propylene glycol ; Propylene Glycol - pharmacokinetics ; Skin - metabolism ; Skin Absorption - drug effects ; Solubility ; Technology, Pharmaceutical - methods ; Time Factors ; Transdermal drug delivery systems (TDSs)</subject><ispartof>Drug development and industrial pharmacy, 2003-01, Vol.29 (7), p.785-793</ispartof><rights>2003 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2003</rights><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c447t-a9ce51dfa6b37129ed2819e3d83346c0aaef8b0b5553d07f11fec1bbf47fd0983</citedby><cites>FETCH-LOGICAL-c447t-a9ce51dfa6b37129ed2819e3d83346c0aaef8b0b5553d07f11fec1bbf47fd0983</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14954504$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12906336$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Funke, Adrian Peter</creatorcontrib><creatorcontrib>Günther, Clemens</creatorcontrib><creatorcontrib>Müller, Rainer Helmut</creatorcontrib><creatorcontrib>Lipp, Ralph</creatorcontrib><title>Development of Matrix Patches for Transdermal Delivery of a Highly Lipophilic Antiestrogen</title><title>Drug development and industrial pharmacy</title><addtitle>Drug Dev Ind Pharm</addtitle><description>Abstract
The aim of this study was to develop matrix-type transdermal systems (TDSs) containing the highly lipophilic (log P = 5.82) antiestrogen (AE) and the permeation enhancers propylene glycol and lauric acid. For that purpose, permeation of AE from various adhesive matrices through excised skin of hairless mice was evaluated. It was found that pretreatment of the skin with permeation enhancers raised the transdermal flux of subsequently applied antiestrogen. Highest steady-state transdermal fluxes (1.1 µg cm−2 h−1) were obtained from Gelva®, polyacrylate adhesive, followed by 0.55 µg cm−2 h−1 from Oppanol® polyisobutylene, 0.31 µg cm−2 h−1 from BIO-PSA® silicone, and 0.12 µg cm−2 h−1 from Sekisui polyacrylate matrices. In order to develop TDS with high content of fluid permeation enhancer propylene glycol, two different strategies were investigated. One strategy was the addition of hydroxypropyl cellulose (HPC) as thickening agent to Gelva matrices. This allowed for propylene glycol loading levels of up to 30%, resulting in transdermal AE fluxes of 0.09 µg cm−2 h−1. On the other hand, a fleece-laminated backing foil was loaded with the described permeation enhancer formulation and laminated with polyacrylate adhesive layer, resulting in transdermal AE fluxes of 0.06 µg cm−2 h−1. However, application of these TDSs on skin pretreated with permeation enhancers raised the fluxes to 2.6 µg cm−2 h−1 from Gelva HPC and 0.46 µg cm−2 h−1 from fleece Sekisui.</description><subject>Adhesives - therapeutic use</subject><subject>Administration, Cutaneous</subject><subject>Animals</subject><subject>Antiestrogen</subject><subject>Biological and medical sciences</subject><subject>Chemistry, Pharmaceutical - methods</subject><subject>Estrogen Receptor Modulators - pharmacokinetics</subject><subject>General pharmacology</subject><subject>Highly lipophilic drug</subject><subject>In Vitro Techniques</subject><subject>Lauric acid</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Hairless</subject><subject>Permeability - drug effects</subject><subject>Permeation enhancers</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>Propylene glycol</subject><subject>Propylene Glycol - pharmacokinetics</subject><subject>Skin - metabolism</subject><subject>Skin Absorption - drug effects</subject><subject>Solubility</subject><subject>Technology, Pharmaceutical - methods</subject><subject>Time Factors</subject><subject>Transdermal drug delivery systems (TDSs)</subject><issn>0363-9045</issn><issn>1520-5762</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNqF0bFv1DAUBnALgehRGFmRF7qF2nEcJ2N1BxTpKhjKwmK9OM-NKycOdq70_ntc3UHFUDG95feeP30m5C1nHzhr-Plmsy54yVjJlWqekRWXJSukqsvnZMVELYqWVfKEvErpljFetlK-JCd5slqIekV-bPAOfZhHnBYaLL2CJbp7-g0WM2CiNkR6HWFKPcYRPN2gd3cY9w8U6KW7Gfyebt0c5sF5Z-jFtDhMSww3OL0mLyz4hG-O85R8__Txen1ZbL9-_rK-2BamqtRSQGtQ8t5C3QmVg2FfNrxF0TdCVLVhAGibjnVSStEzZTm3aHjX2UrZnrWNOCVnh7tzDD93-XU9umTQe5gw7JJWQpZSqPK_kCvZ1lXDMiwO0MSQUkSr5-hGiHvNmX5oXefW9d_Ws393PLzrRuwf9bHmDN4fASQD3uZGjUuPrmplJVmVXXNwbsrNj_ArRN_rBfY-xD9L4qkM6p_VAcEvg4GI-jbs4pR_4In0vwGrMq6u</recordid><startdate>20030101</startdate><enddate>20030101</enddate><creator>Funke, Adrian Peter</creator><creator>Günther, Clemens</creator><creator>Müller, Rainer Helmut</creator><creator>Lipp, Ralph</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20030101</creationdate><title>Development of Matrix Patches for Transdermal Delivery of a Highly Lipophilic Antiestrogen</title><author>Funke, Adrian Peter ; Günther, Clemens ; Müller, Rainer Helmut ; Lipp, Ralph</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c447t-a9ce51dfa6b37129ed2819e3d83346c0aaef8b0b5553d07f11fec1bbf47fd0983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adhesives - therapeutic use</topic><topic>Administration, Cutaneous</topic><topic>Animals</topic><topic>Antiestrogen</topic><topic>Biological and medical sciences</topic><topic>Chemistry, Pharmaceutical - methods</topic><topic>Estrogen Receptor Modulators - pharmacokinetics</topic><topic>General pharmacology</topic><topic>Highly lipophilic drug</topic><topic>In Vitro Techniques</topic><topic>Lauric acid</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Hairless</topic><topic>Permeability - drug effects</topic><topic>Permeation enhancers</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>Propylene glycol</topic><topic>Propylene Glycol - pharmacokinetics</topic><topic>Skin - metabolism</topic><topic>Skin Absorption - drug effects</topic><topic>Solubility</topic><topic>Technology, Pharmaceutical - methods</topic><topic>Time Factors</topic><topic>Transdermal drug delivery systems (TDSs)</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Funke, Adrian Peter</creatorcontrib><creatorcontrib>Günther, Clemens</creatorcontrib><creatorcontrib>Müller, Rainer Helmut</creatorcontrib><creatorcontrib>Lipp, Ralph</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Drug development and industrial pharmacy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Funke, Adrian Peter</au><au>Günther, Clemens</au><au>Müller, Rainer Helmut</au><au>Lipp, Ralph</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of Matrix Patches for Transdermal Delivery of a Highly Lipophilic Antiestrogen</atitle><jtitle>Drug development and industrial pharmacy</jtitle><addtitle>Drug Dev Ind Pharm</addtitle><date>2003-01-01</date><risdate>2003</risdate><volume>29</volume><issue>7</issue><spage>785</spage><epage>793</epage><pages>785-793</pages><issn>0363-9045</issn><eissn>1520-5762</eissn><abstract>Abstract
The aim of this study was to develop matrix-type transdermal systems (TDSs) containing the highly lipophilic (log P = 5.82) antiestrogen (AE) and the permeation enhancers propylene glycol and lauric acid. For that purpose, permeation of AE from various adhesive matrices through excised skin of hairless mice was evaluated. It was found that pretreatment of the skin with permeation enhancers raised the transdermal flux of subsequently applied antiestrogen. Highest steady-state transdermal fluxes (1.1 µg cm−2 h−1) were obtained from Gelva®, polyacrylate adhesive, followed by 0.55 µg cm−2 h−1 from Oppanol® polyisobutylene, 0.31 µg cm−2 h−1 from BIO-PSA® silicone, and 0.12 µg cm−2 h−1 from Sekisui polyacrylate matrices. In order to develop TDS with high content of fluid permeation enhancer propylene glycol, two different strategies were investigated. One strategy was the addition of hydroxypropyl cellulose (HPC) as thickening agent to Gelva matrices. This allowed for propylene glycol loading levels of up to 30%, resulting in transdermal AE fluxes of 0.09 µg cm−2 h−1. On the other hand, a fleece-laminated backing foil was loaded with the described permeation enhancer formulation and laminated with polyacrylate adhesive layer, resulting in transdermal AE fluxes of 0.06 µg cm−2 h−1. However, application of these TDSs on skin pretreated with permeation enhancers raised the fluxes to 2.6 µg cm−2 h−1 from Gelva HPC and 0.46 µg cm−2 h−1 from fleece Sekisui.</abstract><cop>Colchester</cop><pub>Informa UK Ltd</pub><pmid>12906336</pmid><doi>10.1081/DDC-120021778</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0363-9045 |
ispartof | Drug development and industrial pharmacy, 2003-01, Vol.29 (7), p.785-793 |
issn | 0363-9045 1520-5762 |
language | eng |
recordid | cdi_proquest_miscellaneous_73525372 |
source | EBSCOhost Business Source Ultimate; Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list) |
subjects | Adhesives - therapeutic use Administration, Cutaneous Animals Antiestrogen Biological and medical sciences Chemistry, Pharmaceutical - methods Estrogen Receptor Modulators - pharmacokinetics General pharmacology Highly lipophilic drug In Vitro Techniques Lauric acid Male Medical sciences Mice Mice, Hairless Permeability - drug effects Permeation enhancers Pharmaceutical technology. Pharmaceutical industry Pharmacology. Drug treatments Propylene glycol Propylene Glycol - pharmacokinetics Skin - metabolism Skin Absorption - drug effects Solubility Technology, Pharmaceutical - methods Time Factors Transdermal drug delivery systems (TDSs) |
title | Development of Matrix Patches for Transdermal Delivery of a Highly Lipophilic Antiestrogen |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T04%3A27%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20Matrix%20Patches%20for%20Transdermal%20Delivery%20of%20a%20Highly%20Lipophilic%20Antiestrogen&rft.jtitle=Drug%20development%20and%20industrial%20pharmacy&rft.au=Funke,%20Adrian%20Peter&rft.date=2003-01-01&rft.volume=29&rft.issue=7&rft.spage=785&rft.epage=793&rft.pages=785-793&rft.issn=0363-9045&rft.eissn=1520-5762&rft_id=info:doi/10.1081/DDC-120021778&rft_dat=%3Cproquest_cross%3E73525372%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c447t-a9ce51dfa6b37129ed2819e3d83346c0aaef8b0b5553d07f11fec1bbf47fd0983%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=17596480&rft_id=info:pmid/12906336&rfr_iscdi=true |